Entrectinib May Be Effective, Well Tolerated Against ROS1-, NTRK-Positive Cancers
Integrated analyses showed entrectinib to be both effective and well tolerated in patients with rare ROS1 and NTRK gene fusions.
Related Articles
Two Decades of Collaboration: The Accelerating Anticancer Agent Development and Validation (AAADV) Workshop
Over the past 20 years, the investment in research and development of cancer therapies has been unprecedented, and the pace of new drug development has…
Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer
This secondary analysis of a randomized clinical trial examines the use of pharmacogenetic-informed prescribing of fluoropyrimidines and/or irinotecan in patients with gastrointestinal cancer.
Our Legacy of Cancer Research Excellence – UChicago Medicine
For more than 50 years, the University of Chicago has been a leader in cancer research. Our scientists and clinicians have consistently expanded the boundaries…
S09 E01 Tumor-Agnostic Therapies: Is The TAPUR Study Right For You? – Our MBC Life
For our Season 9 opening episode, we’re learning about agnostic treatments in cancer with Dr. Richard Schilsky of ASCO, who discusses the TAPUR Study. You may wonder,…
Tumor-Agnostic Therapies: Is The TAPUR Study Right For You? — Our MBC Life
For our Season 9 opening episode, we’re learning about agnostic treatments in cancer with Dr. Richard Schilsky of ASCO, who discusses the TAPUR Study. You…
Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study | JCO Precision Oncology
PURPOSE Targeted Agent and Profiling Utilization Registry (TAPUR) is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients…
Why Evidence Generation Should Matter to Payers and How They Can Help
This Special Communication discusses the current clinical trials system, examines why payers should support evidence generation, and suggests potential avenues for collaboration.
Why Evidence Generation Should Matter to Payers and How They Can Help
This Special Communication discusses the current clinical trials system, examines why payers should support evidence generation, and suggests potential avenues for collaboration.
A call to action to advance patient‐focused and decentralized clinical trials
This commentary is a call to action for a concerted commitment and effort to transform clinical trials and enable people with cancer to participate in…